The Basel, Switzerland-based biotech company Roche has named a new corporate executive committee.
Pascal Soriot, currently CEO of Genentech, a Roche subsidiary, and a member of the corporate executive committee, has been appointed chief operating officer (COO) of the pharmaceutical division. Jean-Jacques Garaud, the head of pharmaceutical development, has been appointed a member of the enlarged executive committee and assumes responsibility for Roche pharmaceutical research and early development.
Dan Zabrowski, head of pharmaceutical partnering, has been appointed member of the enlarged executive committee. Daniel O’Day, currently had of Roche Molecular Diagnostics, has been named COO of the diagnostics division and a member of the executive committee, while Ian Clark, current head of global product strategy pharmaceutical, replaces Soriot as CEO of Genentech. All of the appointments are effective Jan. 1, 2010.
At the end of this year, William Burns, CEO of the pharmaceutical division, Juergen Schweizer, CEO of the diagnostics division, and Jonathan Knowles, the head of group research, will resign from the executive committee. Schweitzer and Knowles will retire, while Burns will be proposed as a member of the Roche Board at the annual shareholders meeting in 2010.